Clinical Trial Update: Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study [Phase 3]

View source ↗

Summary

Phase 3 Einstein-Extension study evaluating once-daily rivaroxaban for long-term prevention of recurrent symptomatic venous thromboembolism after an initial dee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Pulmonary Embolism
• Venous Thromboembolism

Drugs mentioned

• Xarelto (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Venous Thromboembolism | Phase 3 | Status: COMPLETED | Results posted: 2012-04-12